ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

ANTICANCER RESEARCH is published monthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press.

For more information please visit our websites www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.

Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org. IIAR website: www.iiar-anticancer.org

Selection of Recent Articles

Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). M.G. FURY, S. BAXI, R. SHEN, K.W. KELLY, B.L. LIPTON, D. CARLSON, H. STAMBUK, S. HAQUE, D.G. PFISTER (New York, NY, USA)

Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study). W. ZHANG, M. AZUMA, G. LURJE, M.A. GORDON, D. YANG, A. POHL, Y. NING, P. BOHANES, A. GERGER, T. WINDER, E. HOLLYWOOD, K.D. DANENBERG, L. SALTZ, H.-J. LENZ (Los Angeles; CA; New York, NY, USA)

Oxidative stress decreases Na+, H+ exchange (NHE) activity in a biliary epithelial cancer cell line (Mz-Cha-1). C. ELSING, A. Voss, T. HERRMANN, I. KAISER, C.A. HUEBNER, T. SCHLENKER (Dorsten; Heidelberg; Jena, Germany)

MicroRNA-184-Mediated Inhibition of Tumour Growth in an Orthotopic Murine Model of Neuroblastoma. A. TIVNAN, N.H. FOLEY, L. TRACEY, A.M. DAVIDOFF, R.L. STALLINGS (Dublin; Ireland; Memphis, TN, USA)

Remodeling of the Tumor Microenvironment by Combined Treatment with a Novel Radiosensitizer, α-Sulfoquinovosylmonoacylglycerol (α-SQMG) and X-irradiation. K. OHTA, H. MURATA, Y. MARI, M. ISHIMA, F. SUGAWARA, K. SAKAGUCHI, M. MIURA (Tokyo; Chiba, Japan)

Inhibition of Notch Signaling Reduces the Stem-like Population of Breast Cancer Cells and Prevents Mammosphere Formation. P. GRUDZIEN, S. LO, K.S. ALBAIN, P. ROBINSON, P. RAJAN, PR. STRACK, T.E. GOLDE, L. MIELE, T. SCHLENKER (Maribor, Slovenia; Buffalo, NY, USA)


Procathepsin D and Cytokines Influence the Proliferation of Lung Cancer Cells. V. VETVICKA, J. VETVICKOVÁ (Louisville, KY, USA)

Experimental Model and Immunohistochemical Comparison of U87 Human Glioblastoma Cell Xenografts in Early Stage Cervical Cancer. P.C. BRADY, T.A. BARONE, R.J. PLUNKETT (Maribor, Slovenia; Buffalo, NY, USA)


Inhibition of BCL-2 in Small Cell Lung Cancer Cell Lines with Oblimersen, an Antisense BCL-2 Oligodeoxynucleotide (ODN): In Vitro and In Vivo Enhancement of Radiation Response. Y. LORIOT, R. BAROLI, B.D. BROWN, J. BOURHIS, J.-C. SORIA, E. DEUTSCH (Villejuif; Paris; France; Berkeley Heights, NJ, USA)

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST
Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.
*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

*Submission of Manuscripts.* Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org (mail to: journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO and CANCER GENOMICS & PROTEOMICS
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
CANCER GENOMICS & PROTEOMICS

Print ISSN: 1109-6535
Online ISSN: 1790-6245

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press: For more information please visit our websites www.iiar-anticancer.org and www.iiarjournals.org.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece, Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org (Editorial Office); IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org
Free specimen copies of CGP are available on request.

A Selection of Recent Papers

- Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALLDRIDGE, S. SOUCHELNYTSKYI (Stockholm; Uppsala, Sweden; Chelmsford, UK; Gliwice, Poland; Gold Coast, QLD, Australia)

- Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y. OH, X. YANG, A. FRIEDMAN, C.M. ANSELL, J. DUQUITON, D.F. QUITON, P.A. WOOD, W.J.M. HRUSHESKY (Columbia, SC; St. Louis, MO, USA)


- A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG, R.-P. HUANG (Norcross, GA, USA; Guangzhou, P.R. China)

- TGF-β1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

- Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

- Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, F. PONTÉN, M. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQVIST, M. LILJESTRÖM, K. HELLSTRÖM (Uppsala; Örebro; Gävle; Karlstad; Stockholm; Sweden; Mumbai, India)

- Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T. KAGEYAMA, K. YAMASHITA, A. KAWASHIMA, T. NAKAMURA, A. YAMAMOTO, N. YAMAZAKI, S. YOSHIKAWA, Y. NAKAMURA, Y. KIYOHARA, Y. AKIYAMA (Shizuoka; Tokyo; Saitama, Japan)

- Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O’MEARA, S. CRUET-HENNEQUART, M.P. CARTY (Galway, Ireland)


- DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

- Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUAHAILI, S. ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA)

- Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (Regensburg; Munich, Germany)


Effect of Melatonin on Cyclooxygenase-2 Expression and Nuclear Factor-Kappa B Activation in RAW264.7 Macrophage-like Cells Stimulated with Fimbriae of *Porphyromonas gingivalis*. Y. MURAKAMI, K. YUHARA, N. TAKADA, T. ARAI, S. TSUDA, S. TAKAMATSU, M. MACHINO, S. FUJISAWA (Saitama, Japan) ................................................................................................................................. 641

Morphological Features of Osteoblasts Cultured on Ultraviolet-irradiated Titanium Plates. R. GARCÍA-CONTRERAS, S. KANAGAWA, Y. BEPPU, T. NAGAO, H. SAKAGAMI, H. NAKAJIMA, J. SHIMADA, K. ADACHI (Toluca, México; Saitama, Japan) .................................................................................................................................................... 649

Effects of Grape Extracts on the *In Vitro* Activity of Enzymes Involved in Oxidative Stress Regulation. C. SPANOU, A.S. VESKOUKIS, D. STAGOS, K. LIADAKI, M. ANASTASIADI, S.A. HAROUTOUNIAN, M. TSOUKA, E. TZANAKOULI, D. KOURETAS (Larissa; Athens, Greece) .............................................................................................................................................. 657

The Effect of *CYP1A1* and *GSTM1* Gene Polymorphisms in Bladder Cancer Development in a Turkish Population. T. ÖZTÜRK, Ö.T. KAHRAMAN, B. TOPTAŞ, H.I. KISAKESEN, C. ÇAKALIR, L. VERIM, O. ÖZTÜRK, T. İSBİR (Istanbul, Turkey) .................................................................................................................................................. 663


Clinical Studies

Proliferation of the Synovial Lining Cell Layer in Suggested Metal Hypersensitivity. A. BURKANDT, A. KATZER, K. THALER, V. VON BAEHR, R.E. FRIEDRICH, W. RÜTHER, M. AMLING, J. JUSTIN (Hamburg; Lauf ad Pegnitz; Berlin, Germany) .......................................................................................................................................................................................... 679

Cytoreductive Surgery plus Hyperthermic Intraabdominal Chemotherapy in Elderly Patients. A. MACRÌ, E. SALADINO, G. TRIMARCHI, V. BARTOLO, M. ROSSITTO, A. CANNAÒ, A. RIZZO, C. FAMULARI (Messina, Italy) .............................................................................................................................................................................. 687

Cervical Cone Measurements and Residual Disease in LLETZ Conisation for Cervical Intraepithelial Neoplasia. D. PAPOUTSIS, A. RODOLAKIS, A. ANTONAKOUL, M. SINDOS, S. MESOGITIS, M. SOTIROPOULOU, G. SAKELLAROPOULOS, A. ANTSAKLIS (Athens, Greece) .............................................................................................................................................................................. 691

The Effect of Smoking on Post-operative Finger Range of Motion in Patients with Tendon Grafts. I. JUSTAN, P. OVESNÁ, T. KUBEK, P. HÝŽA, I. STUPKA, Z. DVOŘÁK (Brno, Czech Republic) .............................................................................................................................................................................................................. 697

Contents continued on the preceding page